Why does AI use in healthcare create regulatory risk even when a BAA exists?

A BAA helps define permitted use, but it does not fully govern every AI training, inference, and subprocessor path. The risk grows when PHI moves through multiple vendors and runtime interactions that the contract does not instrument or audit in real time.

Why a BAA does not fully control AI handling of PHI

A BAA is important because it allocates HIPAA obligations between a covered entity and a vendor, but it does not automatically make every AI workflow compliant. AI use can introduce extra data paths, transient prompts, cached outputs, logging, model updates, and subprocessors that sit outside the simple contract view. That is where regulatory risk often appears.

When a clinician, developer, or operations team sends PHI into an AI service, the legal question is not only who signed the BAA, but whether each processing step is permitted, disclosed, and controlled. If the service forwards data to another provider, uses it for model improvement, or stores it longer than expected, the contract may lag behind the actual data flow.

That gap matters because healthcare regulation is built around accountability for use, disclosure, safeguards, and minimum necessary handling. AI systems can change context quickly, and a workflow that looks like a single vendor transaction may actually involve multiple processors, regions, and technical operations that were never described clearly in the original agreement.

Where the regulatory exposure comes from in practice

The core risk is mismatch between contractual coverage and technical reality. A BAA usually names the parties and sets baseline obligations, but it may not describe how prompts are retained, how inference logs are handled, whether PHI is used for training, or how subprocessor access is governed. If those details are absent, the organisation has to prove control some other way.

This becomes sharper in AI deployments that route PHI through APIs, retrieval layers, external model hosts, monitoring tools, and support services. Each additional component increases the number of places where data can be duplicated, observed, or retained, and each one may create a separate compliance question. In that sense, the risk is not just “AI in healthcare”, it is the hidden processing chain behind the AI output.

External guidance on data protection and AI governance reflects that same reality. The EU AI Act regulatory framework and the EU General Data Protection Regulation (GDPR) both push organisations toward clearer purpose limitation, control over processing, and accountability for downstream handling, which is exactly what a BAA alone may not prove.

What practitioners should verify before they rely on the BAA

First, verify the full data path, not just the named vendor. You need to know whether PHI is used only for inference, whether it is retained for support or debugging, whether it is shared with subprocessors, and whether any model provider can use it beyond the service you intended. If you cannot trace that path, you cannot confidently rely on the contract as your only control.

Second, verify that the organisation can produce evidence of governance, not just a signed agreement. That means documented vendor scope, retention rules, subprocessor review, access restrictions, and incident handling tied to the actual AI workflow. A useful companion reference is NIST AI Risk Management Framework, because it helps teams connect policy commitments to operational controls.

Third, verify whether the AI use case is genuinely compatible with the category of PHI being processed. If the workflow touches highly sensitive records, the bar should be higher: more limited data exposure, tighter retention, stronger logging review, and a clearer decision on whether the AI service is even appropriate for that use case.

Risk and Threat Considerations

AI workflows can create regulatory exposure even without a direct breach, because the failure mode is often uncontrolled disclosure or unsupported processing rather than outright theft. The problem is especially acute when PHI moves through multiple vendors, because each handoff expands the chance that a prohibited use, undocumented retention, or unsupported subprocessor relationship slips past the original BAA.

Failure mechanism: The organisation assumes the BAA covers the whole AI chain, but the actual workflow includes prompts, logs, caches, model tuning paths, and subprocessors that were not fully constrained or auditable.

Impact: That gap can create HIPAA exposure, contractual noncompliance, reporting obligations, and avoidable patient-data handling risk even when no obvious security incident has occurred.

Practitioner Guidance

What to prioritise: Treat the AI vendor list as a processing map, not a procurement list. The first decision is whether you can explain where PHI goes, who can see it, how long it is kept, and whether any secondary use is allowed.

What to verify: Require evidence for retention, subprocessor disclosure, logging, and training-use restrictions before production rollout. If those cannot be validated operationally, the BAA should be treated as necessary but insufficient.

Common mistake: Teams often stop at “the vendor signed a BAA” and skip the harder question of whether the deployed AI service is actually behaving within the boundaries the contract assumes.

Practitioner takeaway: In healthcare AI, compliance risk is usually created by the uninstrumented data path, not by the presence or absence of a contract signature, so the control objective is verifiable processing boundaries.

Related resources from NHI Mgmt Group

• Why do AI systems in healthcare create regulatory risk even when they are not explicitly named in a law?
• Why do AI coding agents create security risk even when they use the same model?
• Why do AI systems create legal risk even when no new AI-specific law exists?
• Why do AI use cases in healthcare create more compliance risk than standard analytics projects?